Bluprynt | $4,250,000 | (Feb 27, 2026)
UpGuard | $75,000,000 | (Feb 27, 2026)
Revel(US) | $150,000,000 | (Feb 27, 2026)
Certified by Founder
Lodge
Deverra Therapeutics
start up
United States
- Seattle
- 20/09/2023
- Unknown
- $2,400,000
Deverra Therapeutics is a clinical stage biotechnology company dedicated to the development of allogeneic, off-the-shelf cellular immunotherapies for on-demand treatment of patients with cancer and infectious diseases. The company has an exclusive license to a proprietary stem cell expansion and directed-differentiation platform from the Fred Hutchinson Cancer Research Center based on more than 20 years of federally funded research and data from 5 clinical trials. This platform can be used to generate a range of unmodified and modified immune cells to treat patients with cancer and infectious diseases.
- Industry Biotechnology
- Website https://www.deverratx.com/
- LinkedIn https://www.linkedin.com/company/deverra-therapeutics/about/
Alpa | $3,500,000 | (Feb 27, 2026)
ElastixAI | $18,000,000 | (Feb 27, 2026)
Callosum | $10,250,000 | (Feb 27, 2026)
JetScale AI | $5,400,000 | (Feb 27, 2026)
Dots | $8,900,000 | (Feb 27, 2026)
VITURE | $100,000,000 | (Feb 27, 2026)
Ark Climate | $2,478,315 | (Feb 27, 2026)
Jest | $7,000,000 | (Feb 27, 2026)
Sinergy Flow | $8,273,230 | (Feb 26, 2026)